Strata Oncology Inc. announced enrollment of the first patient in the Strata Sentinel trial, a prospective, observational study that will evaluate the ability of the investigational StrataMRD test to detect cancer recurrence in advance of standard of care techniques across solid tumors, as well as the clinical benefit of treatment in early-stage patients who are or become ctDNA-positive after surgery or other therapy with curative intent.
Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.
